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Abstract Bacterial lox-Cre recombination within a single anti- 
body VH domain was achieved through integration of a loxP site 
into its coding sequence. The 5' half of the VII gene, in which the 
H2 loop was replaced by a mutant loxP site, was fused to genelII 
in an 'acceptor' fd-phage vector containing also a wild type loxP 
site. With a 'donor' plasmid vector harboaring the 3' half of the 
VII gene flanked by the same, differing loxP sites it recombined 
into a full-length VH with the loxP site-H2 loop. This VH was 
purified from bacterial periplasm, where it folded into a typical 
immunoglobulin domain. The system allows the generation of 
large VH repertoires using lox-Cre recombination. 
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and heavy chain genes in the case of Fab fragments. Then the 
two loxP sites, which remain after Cre recombination, are easily 
accomodated: one is placed outside of the genes to be recom- 
bined, while the other is positioned between them. 
To achieve loxCre recombination of a single polypeptide 
chain in bacteria, the placing of the loxP site in between the two 
DNA fragments to be recombined becomes more difficult. One 
of the remaining loxP site must either be spliced out on the 
RNA level or it has to be integrated into the coding sequence 
of the gene itself. To ultimately prepare a large repertoire of 
single antibody domains we describe here the integration of a 
loxP site into the middle of the coding sequence of a camelised 
human VH domain to achieve recombination of two halves of 
the VH gene while located on seperate replicons. 
1. Introduction 
The Cre recombinase of bacteriophage P1 recognises a 34 
base pair DNA sequence (loxP site), which consists of two 
inverted repeats eperated by an 8 base pair spacer [1,2]. I f  two 
loxP sites of identical sequence are present on a DNA fragment, 
Cre recombinase catalyses deletion of the sequence between the 
two sites. A single point mutation in the spacer sequence be- 
tween the inverted repeats in only one of two loxP sites on a 
single piece of DNA can prevent deletion through Cre recombi- 
nation [2]. However, combinatorial exchange with a second 
DNA fragment akes place, if this is flanked by the same differ- 
ing loxP sites present on the first DNA fragment. 
Using such a system, it was possible to recombine two seper- 
ate repertoires of genes from different replicons to generate and 
display a large library of antibody Fab fragments on phage 
[3,4]. The resulting repertoire with more than 101° members 
allowed the antigen driven selection of antibody Fab fragments 
with dissociation constants for their ligands in the nanomolar 
range [4]. 
The same strategy can easily be adopted for bacterial recom- 
bination of other (poly)peptide based recognition units as long 
as they are encoded by at least two seperate genes like the light 
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Abbrev&tions: CD, circular dichroism; CDR1, CDR2, CDR3, comple- 
mentarity determining regions 1, 2 and 3; Fab, antigen binding anti- 
body fragment; Fv, heterodimer ofVH and VL; H 1, H2, H3, hypervar- 
iable loops 1, 2 and 3; NMR, nuclear magnetic resonance; PCR, poly- 
merase chain reaction; SDS, sodium dodecyl sulphate; VH, heavy chain 
variable domain; VL, light chain variable domain. Amino acids are 
abbreviated using the one letter code; mutations are denoted by the wild 
type amino acid followed by the residue number and the new amino 
acid. 
2. Experimental 
2.1. Vectors and recombination 
The vector fd-loxA (Fig. 1) was prepared by cloning the 5' half of the 
camelised, human antibody VH domain VH-P37 (identical to VH-P1 
[5] except for residue 37 (V37F) mutated for a different purpose) into 
the vector fd-21oxvkdel [4]. The fd vector fd-VH harbouring the gene 
for VH-P37 between the leader and the remainder of the fd-genelII [6] 
was amplified using PCR with oligonucleotides fdPCRBAK [7] and 
fdLOXFOR (5'-TTT GCA TGC CTG CAG ATA ACT TCG TAT 
AGT ATA CAT TAT ACG AAG TTA TAG CTGA GAC CCC CTC- 
3'). Following restriction with PstI and ApaLI the PCR product con- 
taining the loxP511 site was cloned into fd-21oxvkdel providing awild 
type loxP site. The PstI/NotI fragment between the loxP sites was then 
replaced by stuffer DNA restoring the reading frame throughout the 
genelII-VH fusion (Fig. I). 
The vector pUC-loxB (Fig. 1) was constructed through cloning of the 
3' portion of VH-P37 from fd-VH after amplification by PCR with 
oligonucleotides fdSEQ1 [7] and pUCLOXBAK (5"-GAG TGG GTC 
AAG CTT ATA ACT TCG TAT AAT GTA TAC TAT ACG AAG 
TTA TAC TAC GCA GAC TCC GTG-3') and restriction with HindlII 
and Not! into pUC 19-21oxVHdel [4]. pUCLOXBACK introduced the 
loxP511 site, while the 3' wild type loxP site was provided by pUC19- 
21oxVHdel. 
Recombination fthe vectors fd-loxA and pUC-loxB was principally 
performed as described [3] except for the use of a chloramphenicol 
resistance confering plasmid (S. Williams, A. Nissim, O. Hartley, J.L. 
Harrison, A. Griffiths and G. Winter, in preparation) providing arabi- 
nose inducable Cre expression i stead of phage P1Cmcl.100. Tetracy- 
cline resistant colonies obtained after recombination were tested by 
PCR screening with the primers fdPCRBACK and fdSEQ1 for the 
presence of fd-loxR. 
2.2. Protein preparation and analysis 
To express soluble VH-lox protein the XhoI/NotI fragment of fd- 
loxR was subcloned into the vector pUC-VH47G [6] containing a XhoI 
site at the beginning of CDR 1. For expression bacterial cultures were 
grown overnight at 37°C in rich medium containing ampicillin (100 
mg/1) and 0.1% glucose followed by a three hour induction period at 
30°C with 1 mM isopropyl fl-D-thiogalactopyranoside. VH-lox and 
VH-P37 proteins were purified from the periplasm [8] by IMAC [9,10] 
according to the manufacturer's instructions (Diagen). 
Purified VH was analysed by SDS-polyacrylamide g lelectrophore- 
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sis [11] in the presence and absence offl-mercaptoethanol. TheEllman 
assay [12,13] was used to detect possible free cysteine residues. Circular 
dichroism analysis was performed at a VH concentration f 10/2g/ml 
in phospate buffered saline solution, pH 7, using a Jasco J720 spectro- 
polorimeter connected toa Vigelin III/33 computer and a Neslab RTE- 
110 waterbath through an RS232 interface. Wavelength scans were 
recorded at 20°C. Thermodenaturation was measured by following the 
elipticity at 235 nm in steps of 0.2°C at a rate of 50°/h. 
3. Results and discussion 
3.1. VH domains 
The Fv fragment of an antibody comprises a pair of variable 
domains from heavy (VH) and light chain (VL). It is usually 
viewed as the smallest functional antibody fragment with re- 
spect to antigen binding. However, some early experimental 
evidence indicated that VH domains alone can retain some of 
the antigen affinity [14]. More recently, antigen binding was 
also detected in expression libraries of mouse VH domains [15]. 
For camels even antibodies were discovered, which lack a nat- 
ural light chain partner [16]. Furthermore, antigen binding VH 
domains [6] or size reduced fragments thereof [17] were selected 
in vitro from synthetic phage-display libraries. 
For an efficient antigen driven selection of phage displayed, 
human VH domains non-specific binding of these VH had to 
be reduced through three mutations in the former light chain 
interface (G44E, L45R and W47G [5,6]). These mutations were 
A ) Xhol PstI 
I 
B) 
C) 
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HindXXl  loxP  511 
A A A L N I T S Y N V C Y T K L L G L A A E 0 
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Fig. 1. Lox-Cre recombination 'acceptor' vector fd-loxA (A), 'donor' vector pUC-loxB (B), recombined vector fd-loxR (B) and DNA sequences close 
to the loxP sites in all three vectors (C). 
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CDR3 
Fig. 2. MolScript [31] ribbon diagram of a human antibody VH domain 
taken from the crystal structure of the Fv Pot [32] with the H2 loop in 
CDR2 shown in black. 
introduced to mimic the camelid heavy chains, which occur 
naturally without light chain [16,18]. Then highly specific VH 
domains could be isolated after selection on protein or hapten- 
protein conjugates [6]. However, as found for phage-display 
repertoires of Fv [19] or Fab [20] fragments affinities of isolated 
antibody fragments for antigen were moderate as long as the 
size of the libraries was not bigger than about 10 s. Dramatic 
increases in affinity with dissociation constants in the nano- 
molar range of selected Fab fragments and their ligands were 
only observed when considerably arger libraries (>101° ) were 
used [4]. 
3.2, LoxP site integration 
Libraries of such size cannot be obtained by simple transfor- 
mation of bacteria. In the case of the large Fab library a com- 
binatorial approach was used, in which a light chain library 
displayed on phage was recombined with a heavy chain library 
through infection of bacteria harbouring a plasmid based heavy 
chain repertoire [4]. Site-specific recombination was facilitated 
through the lox-Cre system, for which the heavy chain on the 
'donor' plasmid was flanked by the same two differing loxP 
sites present 3' of the light chain gene on the 'acceptor' phage. 
The two loxP sites on each vector had to be different in se- 
quence to prevent deletion within a vector. Recombination of 
loxP site flanked DNA between the two vectors however took 
place in the bacteria when Cre recombinase was present and 
created a repertoire, which in practice was limited only by the 
number of infective vents. 
To employ the same system to produce large phage-display 
libraries of VH domains 'acceptor' phage and 'donor' plasmid 
vectors (Fig. 1) were designed analogous to those used for the 
recombination of the Fab library. The 'acceptor' fd phage vec- 
tor fd-loxA (confering tetracycline resistance) contains the 5' 
half (from the N-terminus up to the H2 loop) of the camelised 
VH-P37 fused at its N-terminus to the genelII leader peptide. 
At the C-terminus an engineered H2 loop based on the mutant 
loxP511 DNA sequence was integrated into the coding se- 
quence. This was necessary as in the case of bacterial expression 
of a single polypeptide like the VH the recombined gene will 
normally not contain any noncoding sequences between N and 
C-terminus, which would allow accomodation of the 5' of the 
two loxP sites outside of coding DNA. In fd-loxA a second, but 
now wild type loxP site is located between the following stuffer 
DNA and the remainder of genelII. Thus resulting phage par- 
ticles are highly infectious as they contain an intact proteinlI! 
as part of a fusion protein in their coat. 
The 'donor' plasmid vector pUC-loxB (confering ampicillin 
resistance) contains the 3' half of the VH (from the H2 loop to 
the C-terminus). This is flanked by the same loxP sites present 
on the 'acceptor' vector and should therefore allow recombina- 
tion of this region into the 'acceptor' phage when Cre recombi- 
nase is present. Neither phage nor plasmid DNA should recom- 
bine within itself as their two loxP sites were not identical. 
Recombination between the two replicons hould create a 
VH gene, in which the H2 loop residues of the 'wild type' 
VH-P37 (V51-S52-G52a-S53-G54-G55-S56-T57) are replaced 
by 151-T52-S52a-Y52b-N52c-Y53-Y54-T55-K56-L57 (number- 
ing according [21]) resulting in a lengthening of the hypervaria- 
ble loop in CDR2 by two residues. We opted for the H2 loop 
to locate the loxP511 sequence, because VH domains must be 
able to accomodate a variety of sequences in this region, which 
is by definition hypervariable. Use of CDR2 will also allow 
later a seperated randomisation of CDR1 on the 'acceptor' 
phage and CDR3 on the 'donor' plasmid. These two CDRs are 
together with CDR2 the most variable regions of VH genes in 
natural repertoires [21] and their variation will create a reper- 
toire of binding sites around a scaffold formed by the translated 
loxP site in the H2 loop. 
H2 loops identical in length to that in the newly created VH 
were also found among other members of the originating 
germline VH3 gene family [22]. It is worth noting that among 
M A B M 
27kDa 
14.3kDa- -  
Fig. 3. Non-reducing SDS polyacrylamide g lof purified VH-lox (A), 
VH-P37 (B) and molecular weight markers (M). 
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Fig. 4. Circular dichroism spectra (A) and thermodenaturation curves 
(B) of VH-lox (circles) and VH-P37 (squares). 
the residues replaced only those at position 51, 52 and 57 are 
part of regular E-strand in the VH while residues 52a-56 form 
the turn of the H2 loop [23]. 
The two vectors fd-loxA and pUC-loxB were used to per- 
form a Cre recombination. Bacteria harbouring the 'donor' 
plasmid in addition to a second plasmid confering inducable 
Cre recombinase xpression were infected with 'acceptor' 
phage. 30% of resulting tetracycline resistant colonies con- 
tained a recombined VH gene as part of fd-loxR phage DNA 
(Fig. 1). The recombination result was similar to that observed 
for recombination i case of the Fab phage libraries. The re- 
combination frequency should be sufficient o guarantee x- 
pression of a recombined VH-genelII fusion protein from each 
infected bacterium as there are multiple copies of plasmid and 
phage replicons in each cell, which will produce at least 60 
phage particles during an overnight growth period [4]. 
3.3. VH-lox protein 
We then investigated if the resulting VH domain (termed 
VH-lox) still formed the same general protein fold as the VH 
with the wild type CDR2. The VH-lox gene was subcloned from 
fd-loxR into a soluble expression vector allowing correctly 
folded protein to be secreted into the periplasm via the N- 
terminal pectate lyase leader peptide, which is cleaved off dur- 
ing the membrane transport [24]. This system is being widely 
used for soluble expression of antibody fragments [25] and was 
also used for soluble expression of VH-P37, which is identical 
to VH-lox except for its CDR2. Homonuclear NMR spectra of 
VH-P37 (L.R., unpublished) were very similar to those of the 
closely related VH-P8 [23], from which it differs only at postion 
37 (V37F) and 47 (G47I). The solution structure of VH-P8 has 
been solved through NMR spectroscopy [23 and L.R., in prep- 
aration] and is principally identical of that of VH domains in 
intact antibodies (Fig. 2). 
VH-lox was secreted from bacteria just as VH-P37. The pu- 
rification yield for VH-lox was 1.3 mg/1 bacterial culture com- 
pared to 3 mg obtained with VH-P37. Both proteins tested 
negative for free SH-groups and both run as monomers of 
expected size on reducing and non-reducing SDS-poly- 
acrylamide gels (Fig. 3). Therefore the VH typical intramolecu- 
lar disulphide bond between the cysteines at position 22 and 92 
had to be correctly formed in VH-lox, because there were nei- 
ther free SH groups present nor multimeric omplexes formed 
through formation of intermolecular disulphide bridges. 
Circular dichroism analysis (Fig. 4) indicated anti-parallel 
fl-sheets as the predominant secondary structure element in 
both VH domains, which was expected for immunoglobulin 
domain and was also determined from nuclear Overhauser en- 
hancement NMR analysis of the closely related VH-P8 [23]. 
The CD curves had a negative band near 220 nm typical for 
anti-parallel fl-sheets [26]. The maximum at about 235 nm was 
indicative for aromatic or disulphide chromophores [26] and 
could be expected for a folded protein containing eight tyro- 
sines, five phenylalanines and two tryptophans in combination 
with an intramolecular disulphide bond among altogther 121 
(VH-P37) or 124 (VH-lox) VH domain residues. 
We also investigated whether the loxP site based H2 loop in 
VH-lox compromised structural stability. Melting points of 
VH-P37 and VH-lox were determined in thermodenaturation 
experiments by following their elipticity at 235 nm. Both VH 
showed a single denaturation transition between 20°C and 
90°C (Fig. 4). VH-P37 had a melting point (Tin) of 56.9°C, 
whereas VH-lox had a Tm of 51.7°C. Thus VH-lox was some- 
what less stable than VH-P37. However, VH-lox was still con- 
siderably more stable than for example the VH domain of the 
mouse antibody D1.3, whose T m was determined as 43°C [27] 
The difference in folding stability was approximated in terms 
of energy from the denaturation curves and difference in melt- 
ing points. Van't Hoff's enthalpy AHvh of unfolding was esti- 
mated from the denaturation curve of VH-P37 as 87.5 kcal/mol 
(compare quation 22 in [28]) and the enthalpy AS (0.265 kcal/ 
mol.K) calculated as AHvJT m. The difference in free energy 
change of unfolding by thermodenaturation between VH-P37 
and VH-lox was then approximated from AAG=ASvH.P37 ×AT 
m as 1.38 kcal/mol. This effect on the overall stability was 
comparable tothat observed on average for the loss of a mythe- 
lene group in a fully buried residue of barnase (1.5 kcal/mol 
[29]). Thus replacement of the H2 loop in VH-P37 with the loxP 
site sequence did neither altered the principle structure of the 
VH nor did it substantially affect the overall folding stability. 
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4. Outlook 
These results demonstrated that integration of the loxP se- 
quence into the CDR2 coding sequence of a human VH domain 
caused no structural or microbiological problems. The VH-lox 
protein was created through an in vivo recombination experi- 
ment, which exhibited the same recombination frequency as 
one performed with the corresponding loxP site integrated into 
non-coding sequences. The VH-lox protein was purified from 
the bacterial periplasm in amounts comparable to the VH do- 
main with the 'wild type' CDR2, which in itself suggested cor- 
rect folding. CD spectra recorded with VH-lox showed that its 
general fold was identical to that of a typical immunoglobulin 
VH domain consisting of nine anti-parallel orientated fl- 
strands. Furthermore, the loxP-CDR2 had only a small effect 
on the overall stability of the VH domain resulting in a 5°C 
decrease of its melting point. It should be possible to increase 
this stability later through suitable modifications like the muta- 
tion of residue 47 from glycine to isoleucine, which increased 
the stability of the camelised VH-P8 [5] by more than 10°C 
(L.R., unpublished). 
It needs now to be investigated how well the loxP-CDR2 
performs as a scaffold, around which an antigen binding sites 
is formed in a VH domain. Assuming that VH domains utilise 
the three CDRs for their antigen binding sites like a VH in 
combination with a VL [30], a library of 5' VH regions contain- 
ing randomised CDR1 residues in the vector fd-loxA can be 
recombined with a second library of 3' VH portions containing 
randomised CDR3 residues in the vector pUC-loxB. Phage 
selection of the recombined VH-lox library will then reveal if 
the IoxP-CDR2 is suitable as a building block for the formation 
of high affinity ligand binding sites on VH domains. If so, large 
repertoires of VH-lox libraries could also be used for a second- 
ary recombination with light chain repertoires thereby creating 
even more diverse synthetic repertoires of antibody Fv or Fab 
fragments. 
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